Simulations Plus (NASDAQ:SLP) Receives "Outperform" Rating from William Blair

William Blair reiterated their outperform rating on shares of Simulations Plus (NASDAQ:SLP - Free Report) in a report issued on Thursday morning, Benzinga reports.

A number of other analysts have also recently commented on the stock. Craig Hallum reiterated a "buy" rating and issued a $56.00 price target on shares of Simulations Plus in a research note on Wednesday, July 3rd. JMP Securities began coverage on shares of Simulations Plus in a research note on Tuesday, July 16th. They set a "market perform" rating for the company. BTIG Research cut their target price on shares of Simulations Plus from $60.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday. Finally, KeyCorp began coverage on shares of Simulations Plus in a research note on Monday, July 29th. They set an "overweight" rating and a $47.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.50.

Simulations Plus Price Performance

SLP stock traded down $3.02 during trading hours on Thursday, reaching $30.96. The stock had a trading volume of 718,228 shares, compared to its average volume of 129,364. The stock has a market capitalization of $619.51 million, a PE ratio of 64.50 and a beta of 0.69. The stock has a 50-day simple moving average of $33.20 and a 200 day simple moving average of $40.76. Simulations Plus has a fifty-two week low of $29.37 and a fifty-two week high of $51.22.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the sale, the director now owns 3,501,592 shares in the company, valued at $123,186,006.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 60,750 shares of company stock worth $2,145,055 in the last quarter. 20.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Simulations Plus

Hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC raised its stake in Simulations Plus by 1,100.0% in the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company's stock worth $38,000 after purchasing an additional 1,100 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Simulations Plus in the 1st quarter valued at approximately $57,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Simulations Plus in the 1st quarter valued at approximately $70,000. Los Angeles Capital Management LLC acquired a new position in shares of Simulations Plus in the 2nd quarter valued at approximately $206,000. Finally, Arizona State Retirement System acquired a new position in shares of Simulations Plus in the 2nd quarter valued at approximately $218,000. Institutional investors and hedge funds own 78.08% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.